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Rosenberg	et	al.,	(2015)	stated	that	some	individuals	have	almost	immediate	reactions	with	exposure	to	triggers	while	others	do	not	until	well	into	the	post-operative	period.	The	early	phase	presents	as a	masseter	spasm,	tachypnea	(with	spontaneous	ventilation),	tachycardia	as	well	as	an	irregular	heart	heart,	and	a	rapid	exhaustion	of	soda	lime	as	well	as	a	warm	soda	lime	container.	The	anesthesia	provider	will	begin	to	see	an	increased	minute	ventilation,	an	increased	end-tidal	CO2,	and	cardiac	dysrhythmias,	as	well	as	peaked	T	waves.	This	is	secondary	to	the	patient	having	an	increased	PaCO2,	a	metabolic	and	respiratory	acidosis,	and	hyperkalemia	due	to	the	release	of	potassium	into	the	extracellular	space	(Hines	&	Marschall,	2012).	The	intermediate	phase	presents	with	the	continued	irregular	heart	rate	but	the	patient	would	also	be	cyanotic	and	warm	to	the	touch.		There	will	be	dark	blood	in	the	surgical	site	as	oxygen	molecules	would	not	be	able	to	bind	to	hemoglobin	molecules	as	the	body	is	in	an	acidotic	state	as	well	as	the	decreased	transit	time	of	blood	through	the	lungs,	secondary	to	tachycardia.	The	anesthesia	provider	would	thus	observe	an	increasing	core	body	temperature	and	a	decreasing	oxygen	saturation.	There	would	also	be	persistent	cardiac	dysrhythmias	and	peaked	T	waves	secondary	to	hyperkalemia	(Hines	&	Marschall,	2012).The	late	phase	presents	with ageneralized	skeletal	muscle	rigidity	secondary	to	an	increased	intracellular	calcium	and	increased	serum	creatinine	kinase	level.	There	will	be	a	prolonged	bleeding	time	and	cola	colored	urine,	secondary	to	myoglobinuria	associated	with	rhabdomyolysis.	As	the	patient	remains	in	a	hyperkalemic	state,	the	anesthesia	provider	will	continue	to	notice	cardiac	dysrhythmias	and	peaked	T	waves	but	will	begin	to	observe	a	widened	QRS	as	well	as	ventricular	arrhythmias	(Hines	&	Marschall,	2012).
The	topic	of	Malignant	hyperthermia	(MH)	will	be	presented	in	this	poster.	MH	was	chosen	as	the	poster	topic	as	this	is	an	anesthetic	crisis	that	can	occur	following	the	administration	of	triggering	agents.	It	is	of	the	upmost	importance	for	the	anesthesia	providers,	as	well	as	support	staff,	to	be	able	to	recognize	and	respond	to	an	MH	crisis	to	optimize	the	patient’s	outcome.				Banek et	al.,	(2013)	stated	that	MH	is	a	rare	but		potentially	lethal	genetic	disease	process	that	presents	as	muscle	hypermetabolism	upon	exposure	to	certain	anesthetic	agents.	Butterworth	et	al.,	(2013)	stated	that	MH	impacts:1:3000	- 1:15,000	pediatric	patients1:40,000	adult	patients	The	higher	incidence	in	the	pediatric	population	was	seen	in	cases	where	both	a	volatile	agent	and	succinylcholine	were	used.	Inhaled	general/Volatile	anesthetics/	Depolarizing	muscle	relaxants	known	to	trigger	MH:Desflurane																	SevofluraneIsoflurane																		Halothane	Enflurane																			EtherMethoxyflurane							Succinylcholine(Long	&	Ross,	2017).	Most	reported	cases	have	been	in	young	males,	very	few	have	been	reported	in	the	geriatric	population,	and	none	have	been	reported	in	infants,	but	both	sexes	and	all	ages	may	be	affected	(Butterworth	et	al.,	2013).	MH	incidences	greatly	differ	from	country	to	country	and	even	vary	by	geographical	location	within	the	same	country.	This	illustrates	that	different	gene	pools	can	be	impacted	by	this	disease	process.	In	the	United	States,	the	upper	Midwest	appears	to	have	the	greatest	population	of	individuals	that	are	susceptible	to	MH	(Butterworth	et	al.,	2013).	Inheritance	patterns	include:Autosomal	dominant(Hines	&	Marschall,	2012).Rosenberg	et	al.,	(2015)	stated	that	specific	point	mutations	have	been	found	in	the	ryanodine	receptor	gene	(RYR1)	which	is	located	on	chromosome	19.	Abnormalities	have	also	been	found	on	the	dihydropyridine	receptor.	
Clinical Resources
Differential 
Diagnosis 
Malignant	hyperthermia	requires	a	high	degree	of	suspicion	when	early	signs	and	symptoms	are	present.Unfortunately,	the	early	signs	and	symptoms	of	MH	are	nonspecific	and	present	as	other	hypermetabolic	states	would.	The	hypermetabolic	states	in	question	are:Non-MH	RhabdomyolysisMuscle	disuse	atrophyMyotoniaSepsisComplications	of	laparoscopic	surgeryAllergic	reactionsSerotonin	syndromeHyperthyroidism	Neuroleptic	malignant	syndromeBaclofen	with-drawl	syndrome
To	understand	the	pathophysiology	of	MH,	one	must	first	understand	the	normal	physiology	of	muscle	contraction.	In	normal	muscle	physiology,	an	action	potential	causes	membrane	depolarization	which	releases	calcium	(Ca2+)	from	the	sarcoplasmic	reticulum	(SR).	The	Ca2+ is	thus	inserted	into	the	sarcoplasm	via	the	ryanodine	and	dihydropyridine	receptors.	Both	of	these	receptors	are	voltage-gated	ion	channels.	The	Ca2+ then	interacts	with	the	troponin-tropomyosin	complex	which	creates	the	cross-bridge	between	actin	and	myosin	and	a	muscle	contraction	occurs.	At	the	completion	of	the	muscle	contraction,	Ca2+ is	sequestered	back	into	the	sarcoplasmic	reticulum	and	the	another	stimulus	is	needed	to	release	Ca2+ for	a	muscle	contraction	(Schneiderbanger et	al.,	2014).
Underlying 
PathophysiologyIn	MH,	the	mutated	RYR1 gene	receptor	threshold	is	decreased	for	Ca2+release.	The	RYR1 receptors	are	also	resistant	to	the	negative	feedback	loop	(increase	Ca2+ and	magnesium)	that	would	normally	decrease	the	Ca2+conductance.This	equates	to	an	overt	release	of	Ca2+,	in	response	to	lower	levels	of	membrane	depolarization.	This	causes	an	increased	amount	of	Ca2+ to	be	present	in	the	sarcoplasm	which	causes	continuous	and	prolonged	muscle	contractions	when	attached	to	the	troponin-tropomyosin	complex.	Adenosine	triphosphate	(ATP)	is	consumed	in	every	step	of	intracellular	Ca2+ interactions.	These	steps	include:- Decoupling	of	Ca2+ from	troponin- Removal	of	intracellular	Ca2+- Returning (Ca2+)	to	the	SR	and	mitochondria- Extrusion	into	the	extracellular	milieu(Hines	&	Marschall,	2012).	Oxygen	and	glycogen	are	thus	used	in	massive	quantities	by	the	mitochondria	as	the	body	attempts	to	create	more	ATP	in	response	to	the	highly	increased	metabolic	demands.	The	metabolic	byproducts	of	this	process	are	carbon	dioxide	and	lactate.	In	addition,	the	body	produces	massive	amounts	of	heat	as	the	ATP	is	used	by	muscles	for	contraction.	
Long	&	Ross	(2017)	stated	that	if	MH	is	not	treated,	the	body’s	innate	ability	to	maintain	homeostasis	is	overwhelmed	and	this	can	lead	to	cardiovascular	collapse	and	eventually	death.	Therefore,	prompt	recognition	and	intervention	is	necessary	to	prevent	irreversible	damage.	Hirchey Dirksen	et	al.,	(2013)	stated	that	the	MH	response	leads	to	a	variety	of	internal	reactions	secondary	to	the	disruption	of	cell	membranes	such	as	an	increase	in	serum	potassium,	phosphate,	magnesium,	and	myoglobin	in	the	extracellular	fluid.	Furthermore,	the	complications	that	can	occur	include	permanent	skeletal	muscle	damage,	hyperthermia	(core	temperatures	between	39℃ &	41℃),	renal	failure	(secondary	to	rhabdomyolysis),	cardiac	arrest,	and	possible	death.		Some	of	the	short	and	long	term	complications	of	MH	are	rhabdomyolysis	with	an	accompanying	compartment	syndrome,	disseminated	intravascular	coagulation	(DIC),	heart	failure,	pulmonary	edema,	cerebral	edema	with	or	without	herniation,	acute	liver	failure,	shock	secondary	to	a	mixed	metabolic	and	respiratory	acidosis,	bowel	ischemia,	other	end	multi	organ	failure,	cardiac	collapse,	and	eventually	death	(Epocrates:	An	Athenahealth Service,	2018).	
Schneiderbanger et	al.,	(2014)	stated	that	the	severity	of	a	MH	crisis	depends	on	how	quickly	the	disease	process	is	suspected	and	how	rapidly	an	appropriate	treatment	is	initiated.	Once	MH	has	been	recognized,	it	is	imperative	to	discontinue	the	offending	triggering	agent.	Anesthesia	should	immediately	be	converted	to	total	intravenous	anesthesia	(TIVA)	with	the	use	of	IV	opioids,	sedatives,	and	if	the	patient	status	necessitates	it,	a	non	depolarizing	muscle	relaxant.	The	vaporizer	that	was	used	for	administration	of	the	volatile	anesthetic	should	be	removed	and	the	patient	hyperventilated	with	100%	oxygen	at	maximum	fresh	gas	flow	while	an	activated	charcoal	filter	is	placed.	There	must	also	be	an	increase	in	the	minute	volume	by	2x	– 3x	times	the	patient’s	baseline	in	an	attempt	to	flush	the	volatile	anesthetic	from	the	patients	system	while	also	aiming	to	decrease	the	end-tidal	CO2	to	within	normal	limits.		Hirchey Dirksen	et	al.,	(2013)	states	that	the	main	medication	that	should	be	used	in	a	MH	crisis	is	dantrolene	sodium	at	2.5	mg/kg	IV	every	5-10	minutes	based	on	actual	body	weight.	Long	&	Ross	(2017)	state	that	this	medication	interferes	with	the	release	of	Ca2+from	the	SR	which	results	in	a	decrease	in	the	Ca2+ in	the	myoplasm.	This	is	because	dantrolene	is	a	specific	ryanodine	receptor	antagonist.	It	is	recommended	that	36	vials	of	dantrolene	be	stocked	at	any	facility	where	the	causative	agents	of	MH	are	used	to	treat	a	patient	in	MH	crisis	as	they	will	require	a	very	large	quantity	of	dantrolene.	Once	a	MH	crisis	has	been	confirmed,	and	the	administration	of	dantrolene	has	begun,	other	supportive	measures	must	be	started.	Hirchey Dirksen	et	al.,	(2013)	states	to	administer	sodium	bicarbonate	to	correct	the	acid-base	balance	secondary	to	the	mixed	respiratory	and	metabolic	acidosis.	
Banek et	al.,	(2013)	stated	that	MH	is	a	rare	but		potentially	lethal	genetic	disease	process	that	presents	as	muscle	hypermetabolism	upon	exposure	to	certain	anesthetic	agents.	Rosenberg	et	al.,	(2015)	stated	that	the	main	clinical	features	of	MH	are:1) Unexplained	elevation	of	expired	carbon	dioxide	despite	an	increased	minute	ventilation2) Muscle	rigidity	with	an	associated	Rhabdomyolysis3) Hyperthermia	4) Tachycardia5) Acidosis	[metabolic	and	respiratory]6) HyperkalemiaAccording	to	Hirchey Dirksen	et	al.,	(2013),	the	use	of	dantrolene	sodium,	in	combination	with	early	recognition,	accurate	diagnosis,	and	appropriate	treatment,	has	decreased	rates	of	mortality		from	80%	in	the	1970s	to	approximately	5%	as	of	2007.	
Implications Continued
The	patient	must	also	be	cooled	via	administration	of	cold	IV	fluids,	being	packed	with	ice	packs,	having	cold	irrigation	fluids	instilled	into	open	body	cavities	as	well	as	having	a	cold	lavage	of	the	stomach,	rectum,	and	bladder	as	well	as	the	application	of	hypothermia	blanket.	Diuretics,	such	as	furosemide,	must	also	be	administered	to	reduce	the	incidence	of	fluid	overload	as	well	as	the	promotion	of	the	excretion	of	potassium,	sodium,	and	myoglobin.	Dantrolene,	per	20	mg	vial,	also	contains	3	g	of	mannitol,	an	osmotic	diuretic	which	will	help	in	this	process.	To	correct	the	marked	hyperkalemia,	glucose	and	insulin,	as	well	as	sodium	bicarbonate,	calcium	chloride,	or	calcium	gluconate	can	be	administered.	The	patient	can	also	benefit	from	an	antiarrhythmic	to	treat	dysrhythmias	that	have	not	responded	to	the	treatment	of	acidosis	and	hyperkalemia.	The	implementation	of	standard	advanced	cardiac	life	support	(ACLS)	measures	is	paramount	with	the	exception	of	calcium	channel	blockers	which	can	cause	hyperkalemia	and/or	cardiac	arrest		in	the	presence	of	dantrolene.	
In	the	clinical	setting,	the	anesthesia	provider	and	support	staff	must	be	able	to	quickly	address	and	treat	MH.	One	of	the	primary	resources	that	the	healthcare	provider	has	available	is	the	Malignant	Hyperthermia	Association	of	the	United	States	(MHAUS).	This	association	can	help	facilities	prepare	for	an	MH	emergency	as	well	as	manage	a	crisis	in	real	time.	They	can	be	reached	at:	
1-800-644-9737	24	hours	a	day/7	days	a	week	and	providers	are	encouraged	to	call	if	MH	is	suspected	(Malignant	Hyperthermia	Association	of	the	United	States,	2018).Cain	et	al.,	(2014)	stated	that	MH,	a	rare	yet	life-threatening	event,	can	put	clinicians	at	a	disadvantage	if	they	are	unprepared	to	manage	an	MH	crisis.	The	author	of	this	article	went	on	to	indicate	that	a	facilitated	simulation	of	how	to	respond	and	treat	MH	in	a	safe	environment	can	help	clinical	staff	identify	where	improvement	in	gaps	of	knowledge	and	skills	are	needed.	Two	major	points	that	came	from	the	training	exercise	was	the	importance	of	role	assignments,	as	well	as	the	use	of	visual	aids,	when	training	for	an	MH	crisis.	
Figure	1:	Ryanodex,	concentrated	dantrolene	sodium	for	use	in	a	MH	crisis	(Ryanodex,	2018).		
Differential 
Diagnosis
ContinuedThyrotoxocosisPheochromocytomaMetastatic	carcinoidDrug	induced	muscle	injuryMDMA	overdose	Use	of	designed	drugs	of	newpsychoactive	substances	Alpha	PVP	or	“Flakka”Exertional	heat	strokeThermal	dysregulationIatrogenic	overheatingMeperidine/MAOI	overdoseCocaine	intoxification(Epocrates:	An	Athenahealth Service,	2018).	According	to	Rosenberg	et	al.,	(2015),	patients	with	Central	Core	Disease,	(CCD),	Multi-minicore Disease	(MmD),	central	nuclear	myopathy,	and	King-Denborough syndrome	are	predisposed	to	episodes	of	MH.	
